Results 51 to 60 of about 145,467 (273)

Estimation of the warfarin dose with clinical and pharmacogenetic data.

New England Journal of Medicine, 2009
BACKGROUND Genetic variability among patients plays an important role in determining the dose of warfarin that should be used when oral anticoagulation is initiated, but practical methods of using genetic information have not been evaluated in a diverse ...
T. Klein, R. Altman, N. Eriksson, B. Gage, S. Kimmel, M-T M Lee, N. Limdi, D. Page, D. Roden, M. Wagner, M. Caldwell, J. A. Johnson   +11 more
semanticscholar   +1 more source

Translation of a physiologically‐based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post‐partum women

British Journal of Clinical Pharmacology, EarlyView.
Aims To translate a PBPK model developed for the direct oral anticoagulant, dabigatran etexilate, the prodrug of dabigatran, based on data obtained from healthy men to healthy non‐pregnant, pregnant and post‐partum women. To evaluate safety and efficacy of dabigatran etexilate in post‐partum women using simulations and design a future clinical study to
Kayode Ogungbenro, Lorna Aucott, Farhad Kamali, Paul Ayuk   +3 more
wiley   +1 more source

A Case Control Study of Nutrient Intake Deficiencies in Patients Taking Warfarin

Marshall Journal of Medicine, 2015
Introduction We previously published the case of a woman taking warfarin who was found to have scurvy, a disease caused by a deficiency of vitamin C. This led us to hypothesize that patients taking warfarin who consume a diet limited in vitamin K rich
Philip Riley, Kim Lucas Day, George M. Yousef, Sirisha Devabhaktuni, Ashley N. Gaing, Lynne J. Goebel   +5 more
doaj   +1 more source

Cancer patients’ experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis [PDF]

, 2018
Background: Cancer-Associated thrombosis is common. Recommended treatment is daily injected low-molecular-weight heparin for 6months. Most studies focus on prophylaxis and treatment; few have explored patients’ experience.
Benelhaj, Naima B., Hutchinson, Ann, Ilyas, Muhammad Waqas, Johnson, Miriam J., Maraveyas, Anthony M., Seymour, Julie D.   +5 more
core   +1 more source

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2016
Background The introduction of non–vitamin K antagonist oral anticoagulants has been a major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in clinical trials may not translate to routine practice.
Xiaoxi Yao, N. Abraham, L. Sangaralingham, M. Bellolio, R. McBane, Nilay D. Shah, P. Noseworthy   +6 more
semanticscholar   +1 more source

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer

British Journal of Clinical Pharmacology, EarlyView.
Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Catharina J. P. Op 't Hoog, Niven Mehra, Anouk van Kleef, Diederik M. Somford, Inge M. van Oort, Alex L. T. Imholz, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter   +8 more
wiley   +1 more source

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. [PDF]

, 2019
IntroductionPatient-reported outcomes (PROs) and satisfaction endpoints are increasingly important in clinical trials and may be associated with treatment adherence.
Becker, Richard C, Berkowitz, Scott D, Breithardt, Guenter, Fox, Keith AA, Hacke, Werner, Halperin, Jonathan L, Hankey, Graeme J, Hellkamp, Anne S, Mahaffey, Kenneth W, Nessel, Christopher C, Patel, Manesh R, Piccini, Jonathan P, Rodriguez, Fatima, Singer, Daniel E, Ungar, Leo   +14 more
core   +1 more source

Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably! [PDF]

, 2017
No abstract ...
Aspirin Myocardial Infarction Study Research Group, Baigent, Baigent, Bonaca, Chin, Cleland, Cleland, Cleland, Cleland, Cleland, Cleland, Gelder, Homma, Lewis, Massie, Meune, Michel, Pitt, Pitt, Silva, Solomon, Tweeddale, Zannad, Zannad   +23 more
core   +1 more source

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study

British medical journal, 2016
Objective To study the effectiveness and safety of the non-vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) dabigatran, rivaroxaban, and apixaban compared with warfarin in anticoagulant naïve patients with atrial fibrillation ...
T. Larsen, F. Skjøth, P. Nielsen, J. N. Kjældgaard, G. Lip   +4 more
semanticscholar   +1 more source

Machine learning methods for predicting adverse drug events: A systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high‐risk patients and reducing health‐care costs. While traditional methods struggle with the complexity of health‐care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ...
Niaz Chalabianloo, Fatemeh Ahmadi, Mohammad Ali Omrani, Sheikh S. Abdullah, Neda Rostamzadeh, Atefeh Jafari, Lujain Izzedin, Kamran Sedig, Flory T. Muanda   +8 more
wiley   +1 more source